Switzerland's Shield Therapeutics Raises $12M To Conduct Phase III Trials On Oral Iron Deficiency Product
This article was originally published in The Pink Sheet Daily
Oral iron deficiency therapy to advance into Phase III this year on the back of $12 million fund raising for Swiss minnow, Shield Therapeutics.
You may also be interested in...
Shield Therapeutics will use robust Phase III data for its oral iron-deficiency therapy ST10 to seek marketing approval in Europe in the second half of 2014 for iron-deficiency anemia in inflammatory bowel disease, and then a subsequent NDA submission in the U.S. for treating iron-deficiency anemia in pre-dialysis patients with chronic kidney disease.
Plus news on recent financings by Array Biopharma, Delenex Therapeutics, Naurex and Fate Therapeutics.
Anergis raises CHF 18 million from European venture funds to support Phase II study of fast-acting approach to allergy desensitization.